Ann: Quarterly Activity Report & Appendix 4C, page-25

Apologies, Speckled, I read your friends comments and am confused by them. Can you clarify for me?

He said that (and I'm paraphrasing), that the BH deal is a nothing deal that would take the coy nowhere, yet in the same breath, states that the deal helps Orthocell pursue the more lucrative platform in Remplir?

Am I encapsulating that correctly?

I think we all understand that Striate is the least financially promising platform of CelGro they have, and it was always a means to an end as they focus on Remplir with OrthoATI percolating in the background.

The big takeaway from the Striate deal, for me at the very least, was the validation of superior quality of their membrane.

At a Mcap of roughly $77m and a low float of around 198m shares, this thing is could 3, 4 or even 5 bag easy.